A study from China highlighted that extramedullary disease (EMD) significantly impacted the prognosis of patients undergoing anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma (RRMM). Here, TNFRSF17 is linked to plasma cell myeloma.